Delcath Systems to Participate in Upcoming Investor Conferences
Delcath Systems, Inc. (DCTH)
US:NASDAQ Investor Relations:
delcath.com/investors
Company Research
Source: Business Wire
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following upcoming investor conferences:Stephens Biotechnology Virtual Fireside ChatsDate: Wednesday, November 13, 2024Fireside Chat Time: 9:30 am Eastern TimeLocation: Virtual15th Annual Craig-Hallum Alpha Select ConferenceDate: Tuesday, November 19, 20241x1 MeetingsLocation: New York, NYAbout Delcath Systems, Inc., HEPZATO KIT and CHEMOSATDelcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (Hepzato (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic ex
Show less
Read more
Impact Snapshot
Event Time:
DCTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DCTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DCTH alerts
High impacting Delcath Systems, Inc. news events
Weekly update
A roundup of the hottest topics
DCTH
News
- Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer [Yahoo! Finance]Yahoo! Finance
- Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal CancerBusiness Wire
- Delcath Systems Stock (NASDAQ:DCTH) Among the Best Multibagger Stock to Buy Heading into 2025 [Yahoo! Finance]Yahoo! Finance
- Delcath Systems, Inc. (NASDAQ: DCTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock.MarketBeat
- Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
DCTH
Earnings
- 11/8/24 - Beat
DCTH
Sec Filings
- 11/15/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- DCTH's page on the SEC website